TABLE II.
Kruskal–Wallis Analyses and Post Hoc Comparisons
| P-value | |
|---|---|
| 3 Groups miR-122 | <0.001 |
| Acute liver failure vs. chronic hepatitis C | <0.999 |
| Acute liver failure vs. controls | <0.001 |
| Chronic hepatitis C vs. controls | <0.001 |
| 3 Groups hgDNA | <0.001 |
| Acute liver failure vs. chronic hepatitis C | <0.001 |
| Acute liver failure vs. controls | <0.001 |
| Chronic hepatitis C vs. controls | 0.197 |
| 5 Subgroups miR-122 | <0.001 |
| Acetaminophen induced vs. controls | <0.001 |
| Other causes vs. controls | 0.004 |
| Elevated chronic hepatitis C vs. controls | <0.001 |
| Normal chronic hepatitis C vs. controls | 0.040 |
| Acetaminophen induced vs. normal chronic hepatitis C |
0.021 |
| 5 Subgroups hgDNA | <0.001 |
| Acetaminophen induced vs. elevated chronic hepatitis C |
<0.001 |
| Acetaminophen induced vs. normal chronic hepatitis C |
<0.001 |
| Acetaminophen induced vs. controls | <0.001 |
| Other cause vs. normal chronic hepatitis C | 0.042 |
| Other causes vs. controls | <0.001 |
Kruskal–Wallis and post hoc pairwise results comparison for miR-122 and hgDNA across three main study groups and five subgroups. All pairwise results presented for main groups comparison. Only significant pairwise comparisons presented for subgroup analysis.